Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

812
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
812
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

660
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
660
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

3.3K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.3K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

662
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
662
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

569
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
569
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

701
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
701

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders.

International journal of molecular sciences·2026
Same author

The Effect of Dopaminergic Therapies in Parkinson's Disease on Non-Motor Symptoms.

International journal of molecular sciences·2025
Same author

Respiratory and Cardiovascular Activity of LENART01, an Analgesic Dermorphin-Ranatensin Hybrid Peptide, in Anesthetized Rats.

International journal of molecular sciences·2025
Same author

Impaired Breathing During Exposure to Hypoxia and Carotid Body Dysfunction in an Animal Model of Parkinson's Disease.

Comprehensive Physiology·2025
Same author

Molecular Hydrogen in the Treatment of Respiratory Diseases.

International journal of molecular sciences·2025
Same author

A Novel Tetrahydroacridine Derivative with Potent Acetylcholinesterase Inhibitory Properties and Dissociative Capability against Aβ42 Fibrils Confirmed by In Vitro Studies.

International journal of molecular sciences·2024

Related Experiment Video

Updated: Oct 9, 2025

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

43.3K

Regulatory Peptides in Asthma.

Katarzyna Kaczyńska1, Dominika Zając1, Piotr Wojciechowski1

  • 1Department of Respiration Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawińskiego 5 St., 02-106 Warsaw, Poland.

International Journal of Molecular Sciences
|December 24, 2021
PubMed
Summary

Regulatory peptides significantly impact asthma by worsening or improving symptoms. Targeting these peptides offers new therapeutic avenues for difficult-to-treat asthma cases.

Keywords:
airway hyperreactivityasthmainflammationregulatory peptides

More Related Videos

In vitro Measurements of Tracheal Constriction Using Mice
10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

20.9K
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.8K

Related Experiment Videos

Last Updated: Oct 9, 2025

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

43.3K
In vitro Measurements of Tracheal Constriction Using Mice
10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

20.9K
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.8K

Area of Science:

  • Immunology
  • Pharmacology
  • Respiratory Medicine

Background:

  • Asthma pathogenesis involves complex mechanisms including airway inflammation and hyperresponsiveness.
  • Regulatory peptides are key mediators in respiratory diseases, influencing asthma symptoms.
  • Existing asthma therapies are not always effective, necessitating novel treatment strategies.

Purpose of the Study:

  • To review the current understanding of regulatory peptides in asthma.
  • To highlight peptides that exacerbate or ameliorate asthma symptoms.
  • To explore therapeutic potential targeting peptide receptors in asthma.

Main Methods:

  • Literature review of current research on regulatory peptides and asthma.
  • Analysis of the roles of specific peptides (e.g., neuropeptide Y, tachykinins, nociceptin, neurotensin, β-defensin 2).
  • Discussion of therapeutic implications of targeting peptide-receptor interactions.

Main Results:

  • Certain regulatory peptides like neuropeptide Y and tachykinins worsen asthma.
  • Other peptides, including nociceptin, neurotensin, and β-defensin 2, show potential to alleviate asthma symptoms.
  • Peptide receptors in the lungs and on immune cells are viable therapeutic targets.

Conclusions:

  • Regulatory peptides are crucial players in asthma pathology.
  • Targeting specific regulatory peptides or their receptors presents promising therapeutic strategies for asthma, particularly for resistant cases.
  • Further research into peptide-receptor interactions could lead to innovative asthma treatments.